| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Clinodiside A targets pathways involved in inflammation, oxidative stress, and apoptosis. Studies indicate that it can modulate immune responses, reduce oxidative stress, and protect cells from apoptosis. Its anti-inflammatory and hemostatic properties are consistent with its traditional use.
|
|---|---|
| ln Vitro |
In vitro, Clinodiside A demonstrates immunomodulatory, anti-inflammatory, and anti-apoptotic activities. Specific potency data, such as IC50 values, are not widely reported.
|
| ln Vivo |
In vivo, Clinodiside A is used as a quality control index in Clinopodium herb drop pills. Its anti-inflammatory and hemostatic effects are believed to contribute to the therapeutic effects of Clinopodium chinensis in traditional medicine.
|
| Enzyme Assay |
The in vitro anti-inflammatory assay for Clinodiside A involves treating immune cells with the compound and measuring the production of inflammatory cytokines. Its antioxidant activity can be assessed by measuring its ability to reduce ROS levels.
|
| Cell Assay |
In vitro cell culture studies for Clinodiside A utilize immune cells to study its immunomodulatory effects. Its anti-apoptotic effects can be studied in cells treated with apoptotic inducers.
|
| Animal Protocol |
In vivo animal experiments for Clinodiside A are not extensively documented. Its anti-inflammatory effects could be studied in models of acute or chronic inflammation. Its hemostatic effects could be studied in models of bleeding.
|
| ADME/Pharmacokinetics |
Clinodiside A has a molecular weight of 959.12 g/mol and is soluble in DMSO. It is typically stored as a powder at -20°C. Its purity is ≥98%.
|
| Toxicity/Toxicokinetics |
Toxicological data for Clinodiside A are limited, as it is a research compound. As a natural saponin, it may have hemolytic activity at high concentrations. It is not intended for human use. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Clinodiside A is a research compound with no clinical approval. It is a quality control index for Clinopodium herb products and is used in research to study the pharmacology of triterpenoid saponins. Its immunomodulatory, anti-inflammatory, and anti-apoptotic properties make it a compound of interest for research into inflammation and liver diseases.
|
| Molecular Formula |
C48H78O19
|
|---|---|
| Molecular Weight |
959.1215
|
| Exact Mass |
942.518
|
| CAS # |
916347-31-4
|
| PubChem CID |
71571492
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1054.2±65.0 °C at 760 mmHg
|
| Flash Point |
591.3±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.634
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
67
|
| Complexity |
1830
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HVRAMEAUCOTBHH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C48H78O19/c1-43(2)11-12-48(21-52)24(14-43)23-7-8-28-45(4)10-9-22(13-29(45)44(3,20-51)19-47(28,6)46(23,5)15-30(48)53)63-41-38(61)35(58)39(67-42-37(60)34(57)32(55)26(17-50)65-42)27(66-41)18-62-40-36(59)33(56)31(54)25(16-49)64-40/h7-8,22,25-42,49-61H,9-21H2,1-6H3
|
| Chemical Name |
2-[[4,5-dihydroxy-6-[[8-hydroxy-5,8a-bis(hydroxymethyl)-5,6a,6b,11,11,14b-hexamethyl-1,2,3,4,4a,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~104.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0426 mL | 5.2131 mL | 10.4262 mL | |
| 5 mM | 0.2085 mL | 1.0426 mL | 2.0852 mL | |
| 10 mM | 0.1043 mL | 0.5213 mL | 1.0426 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
